Global Wound Care Biologics Market, By Product (Biologic Skin Substitutes, Topical Agents), Wound Type (Ulcers, Surgical and Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers and Wound Clinics) – Industry Trends and Forecast to 2029
Market Analysis and Size
Diabetes has evolved into a common illicit relationship among all developed and agricultural countries. Diabetes is becoming more common by the year, paving the way for major players in the treatment market. The wound care biologics market is one of the winners. The growing diabetic population is thought to be a major factor fuelling the growth of the global wound care biologics market. Numerous diabetic patients suffer from diabetic ulcers, which necessitate minor surgeries and assurance. Following a medical procedure, the patient's wound is typically covered with a swath containing medication for healing. Wound care biologics provide such items, which aid in improving treatment productivity.
Data Bridge Market Research analyses that the wound care biologics market is expected to reach the value of USD 3.11 billion by the year 2029, at a CAGR of 3.80% during the forecast period. The rise in the number of burn injuries is fueling the growth of the wound care biologics market.
Market Definition
Wound healing is a complex process that involves the synchronisation and activation of numerous intracellular, extracellular, and intercellular elements, such as collagen coagulation and deposition, epithelialization, fibrous tissue accretion, wound contraction, inflammatory events, tissue granulation, and remodelling. Wound care biologics are biologically engineered products used to treat non-healing lower extremity wounds.
Report scope and market segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product (Biologic Skin Substitutes, Topical Agents), Wound Type (Ulcers, Surgical and Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centres and Wound Clinics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Smith & Nephew (UK), Mölnlycke Health Care AB (Sweden), Integra LifeSciences Corporation (US), Wright Medical (US), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Organogenesis (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), Lavior Inc. (US). Marine Polymer Technologies, Inc. (US), Smith & Nephew (UK), Mölnlycke Health Care AB (Sweden)
|
|
|
|
|
Opportunities
|
|
|
|
|
|
|
|
Wound care biologics Market Dynamics
Drivers
- The increased diabetes incidence
One of the major factors driving the growth of the wound care biologics market is the increase in wound care treatment and management programmes. The rise in diabetes incidences due to obesity, poor diet, and physical inactivity, as well as the rise in chronic wounds, particularly foot ulcers, among the diabetic population, are driving market growth..
Development of better treatment options
The market is also influenced by the emphasis on the development of better treatment options, as well as the huge burden of diseases and the use of technology to deal with inflammation, tissue accumulation, collagen deposition, and the formation of epithelial cell layers
- Government investments for healthcare interoperability
The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the wound care biologics market.
Opportunities
Improvements in healthcare infrastructure, increased investment in the biotechnology sector, and an increase in healthcare expenditure all have a positive impact on profitable opportunities.
Restraints/Challenges
The high cost of wound treatment and wound care biologics is a factor that is expected to stymie market growth. During the forecast period, the risk of skin substitute failure is expected to pose a challenge to the wound care biologics market.
This wound care biologics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the wound care biologics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Wound Care Biologics Market
Pharmaceutical and biotech companies, in collaboration with governments around the world, are working to address the COVID-19 outbreak, from vaccine development to planning for medicine supply chain challenges. Approximately 115 vaccine candidates and 155 molecules are currently in the R&D pipeline. Furthermore, commonly used drugs such as hydroxychloroquine have seen a dramatic increase in demand for COVID-19 management. Because many developed countries are running low on these drugs, the high demand has created enormous opportunities for manufacturers of COVID-19 management drugs. The pharmaceutical and biotechnology industries are expected to grow significantly in the future due to the demand for COVID-19 vaccines and treatment drugs.
Global Wound Care Biologics Market Scope
The wound care biologics market is segmented on the basis of product, wound type and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Biologic skin substitutes
- Topical agents
On the basis of the product, the wound care biologics market is segmented into biologic skin substitutes and topical agents. Biologic skin substitutes are further segmented into human donor tissue-derived products, acellular animal-derived products and biosynthetic products.
Wound type
- Ulcers
- Surgical and traumatic wounds
- Burns
On the basis of the wound type, the wound care biologics market is segmented into ulcers, surgical and traumatic wounds and burns. Ulcers venous are further segmented into ulcers, diabetic foot ulcers, pressure ulcers and other ulcers.
End User
- Hospitals
- ASCs
- Burn centres
- Wound clinics
- Others
On the basis of the end-user, the wound care biologics market is segmented into hospitals, ascs, burn centers and wound clinics.
Wound Care Biologics Market Regional Analysis/Insights
The wound care biologics market is analysed and market size insights and trends are provided by country, product, wound type and end user. referenced above.
The countries covered in the wound care biologics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the product and wound type due to the increasing prevalence of diabetic foot ulcers and increased susceptibility to microbial and fungal skin infections. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the presence of emerging countries such as China, Japan, and India, as well as developing healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The wound care biologics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for wound care biologics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the wound care biologics market. The data is available for historic period 2010-2020.
Competitive Landscape and Wound Care Biologics Market Share Analysis
The wound care biologics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to wound care biologics market.
Some of the major players operating in the wound care biologics market are
- Smith & Nephew (UK)
- Mölnlycke Health Care AB (Sweden)
- Integra LifeSciences Corporation (US)
- Wright Medical (US)
- MiMedx Group (US)
- Vericel Corporation (US)
- Anika Therapeutics (US)
- Osiris Therapeutics (US)
- Organogenesis (US)
- Kerecis (Iceland)
- Solsys Medical (US)
- ACell (US)
- Lavior Inc. (US)
- Marine Polymer Technologies, Inc. (US)
- Smith & Nephew (UK)
- Mölnlycke Health Care AB (Sweden)
SKU-